Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva starts phase III trial for MS drug
The studies will now begin following the successful conclusion of a second phase II study and the outcome of discussions with the FDA and the European Medicines Agency.
The studies will now begin following the successful conclusion of a second phase II study and the outcome of discussions with the FDA and the European Medicines Agency.
The researchers’ findings suggest that GAB2 modifies an individual’s risk of developing Alzheimer’s disease when associated with other genes, including APOE4. The discovery, which was announced by researchers
The study evaluated the effect of a single application of NGX-4010, the company’s novel dermal patch, on pain due to postherpetic neuralgia (PHN). The primary endpoint in this
The top-line results from the trial comparing Albuferon in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C with Pegasys suggest that Albuferon may offer
Aspreva is currently evaluating CellCept, known generically as mycophenolate mofetil, for the treatment of lupus nephritis in a global phase III study. The FDA’s fast track designation is
As a result of the positive findings, Sangamo expects to initiate a phase I clinical trial to test the HIV ZFP therapy in the second half of 2007.
“By giving the CHF guidance more prominence in the Actos label, we hope to ensure that this information is being attended to by treating physicians to optimize patient
Roche revealed that it is carrying out the recall in agreement and cooperation with the EMEA and Swissmedic health authorities, after receiving several reports that some batches of
The data supporting the NDA showed doripenem was an effective treatment for hospital-acquired, or nosocomial, pneumonia. The data also demonstrated the effectiveness of doripenem against infections caused by
The study is expected to enroll approximately 200 patients at 35 leading multiple sclerosis (MS) clinical centers in the US and Canada. Fifteen centers have been initiated and